New radioactive therapy targets tough childhood cancer

NCT ID NCT04023331

Terminated Disease control Sponsor: Clarity Pharmaceuticals Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a radioactive drug called 67Cu-SARTATE in 21 children with high-risk neuroblastoma that had relapsed or not responded to treatment. The drug is designed to deliver radiation directly to tumor cells. The goal was to find the safest dose and see if it shrinks tumors. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 67Cu-SARTATE (a radioactive drug that targets tumor cells)
What this could lead to: If successful, this could provide a new treatment option for children with hard-to-treat neuroblastoma that has come back or not responded to standard therapy.
What could go wrong: This is an early-phase trial with only 21 participants, so results may not apply broadly. The trial was terminated, which may indicate challenges. Radiation therapy can cause side effects like low blood counts or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA REFRACTORY NEUROBLASTOMA RELAPSED NEUROBLASTOMA

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Centre

Cincinnati, Ohio, 45229, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Phoenix Children's Hospital

Phoenix, Arizona, 85016, United States
University of Texas Southwestern Medical Centre

Dallas, Texas, 75390, United States
University of Wisconsin

Madison, Wisconsin, 53792, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.